VAP-1 INHIBITORS FOR TREATING PAIN
This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.
1 . A VAP-1 inhibitor for use in, or for use in the manufacture of a medicament for, the treatment of pain.
2 . A VAP-1 inhibitor for use in, or for use in the manufacture of a medicament for, the treatment of pain,
PROVIDED THAT
the VAP-1 inhibitor is other than (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-H-imidazo[4,5-c]pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof.
3 . A method for the treatment of pain, which comprises administering to a subject suffering from pain an effective amount of a VAP-1 inhibitor.
4 . A method for the treatment of pain, which comprises administering to a subject suffering from pain an effective amount of a VAP-1 inhibitor,
PROVIDED THAT
the VAP-1 inhibitor is other than (3S)-Tetrahydrofuran-3-yl (4)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof.
5 . A pharmaceutical composition for use in the treatment of pain, which comprises: a VAP-1 inhibitor; and a pharmaceutically acceptable carrier, excipient, or diluent.
6 . A pharmaceutical composition for use in the treatment of pain, which comprises: a VAP-1 inhibitor other than (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-H-imidazo[4,5-c]-pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, excipient, or diluent.
7 . A VAP-1 inhibitor for use according to claim 1 or 2 , or a method according to claim 3 or 4 , or a pharmaceutical composition for use according to claim 5 or 6 , wherein the VAP-1 inhibitor has the structure of any one of the specific Examples of VAP-1 inhibitor compounds, polypeptides or proteins disclosed herein.
8 . A VAP-1 inhibitor for use according to claim 1 or 2 , or a method according to claim 3 or 4 , or a pharmaceutical composition for use according to claim 5 or 6 , wherein the VAP-1 inhibitor is a compound selected from 1-(4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazin-1-yl)ethan-1-one, 1-{5-[3-(4-Fluorophenyl)-3H-Imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-4-methanesulfonylpiperazine, 4-{5-[3-(4-Fluorophenyl-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine, (S)-carbidopa, benserazide, LJP1207, BTT1023, RTU-1096, PXS4728 and ASP8232 or a hydrate or pharmaceutically acceptable salt thereof.
9 . A VAP-1 inhibitor for use according to claim 1 or 2 , or a method according to claim 3 or 4 , or a pharmaceutical composition for use according to claim 5 or 6 , wherein the VAP-1 inhibitor is (S)-carbidopa, or a hydrate or a pharmaceutically acceptable salt thereof.
10 . A VAP-1 inhibitor for use according to claim 1 or 2 , or a pharmaceutical composition for use according to claim 5 or 6 , or any one of claims 7 to 9 , wherein the pain is inflammatory pain.
11 . A VAP-1 inhibitor for use according to claim 1 or 2 , or a pharmaceutical composition for use according to claim 5 or 6 , or any one of claims 7 to 9 , wherein the pain is neuropathic pain.
12 . A method according to claim 3 or 4 , or any one of claims 7 to 9 , wherein the pain is inflammatory pain.
13 . A method according to claim 3 or 4 , or any one of claims 7 to 9 , wherein the pain is neuropathic pain.
14 . A combined preparation for use in, or for use in the manufacture of a medicament for, the treatment of pain, which comprises: a VAP-1 inhibitor and a steroid.
15 . A method for the treatment of pain, which comprises administering to a subject suffering from pain an effective amount of a VAP-1 inhibitor and an effective amount of a steroid.
16 . A pharmaceutical composition for use in the treatment of pain, which comprises: a VAP-1 inhibitor; a steroid; and a pharmaceutically acceptable carrier, excipient, or diluent.
17 . A combined preparation for use according to claim 14 , or a method according to claim 15 , or a pharmaceutical for use composition according to claim 16 , wherein the VAP-1 inhibitor has the structure of any one of the specific Examples of VAP-1 inhibitor compounds, polypeptides or proteins disclosed herein.
18 . A combined preparation for use according to claim 14 , or a method according to claim 15 , or a pharmaceutical composition for use according to claim 16 , wherein the VAP-1 Inhibitor Is a compound selected from 1-(4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazin-1-yl)ethan-1-one, 1-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-4-methanesulfonylpiperazine, 4-{5-[3-(4-Fluorophenyl-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine, (S)-carbidopa, benserazide, LJP1207, BTT1023, RTU-1096, PXS4728 and ASP8232, or a hydrate or a pharmaceutically acceptable salt thereof, and combinations thereof.
19 . A combined preparation for use according to claim 14 , or a method according to claim 15 , or a pharmaceutical composition for use according to claim 16 , wherein the VAP-1 inhibitor is (S)-carbidopa, or a hydrate or a pharmaceutically acceptable salt thereof.
20 . A combined preparation for use according to claim 14 , or a method according to claim 15 , or a pharmaceutical composition for use according to claim 16 , wherein the pain is inflammatory pain.
21 . A combined preparation for use according to claim 14 , or a method according to claim 15 , or a pharmaceutical composition for use according to claim 16 , wherein the pain is neuropathic pain.
22 . A combined preparation for use according to claim 14 , or a method according to claim 15 , or a pharmaceutical composition for use according to claim 16 , wherein the steroid is a glucocorticoid.
23 . A combined preparation for use according to claim 14 , or a method according to claim 15 , or a pharmaceutical composition for use according to claim 16 , wherein the steroid is selected from any one of prednisone, prednisolone, methyl prednisolone, triamcinolone, dexamethasone, hydrocortisone, deflazacort, betamethasone and budenoside, and combinations thereof.
24 . A combined preparation, which comprises: (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof; and a steroid.
25 . A method of treating pain comprising administering to a subject suffering from pain an effective amount of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]-pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof, and an effective amount of a steroid.
26 . A pharmaceutical composition, which comprises: (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof; a steroid; and a pharmaceutically acceptable carrier, excipient, or diluent.
27 . Use of a combined preparation according to claim 24 , or a pharmaceutical composition according to claim 26 , in the manufacture of a medicament for the treatment of pain.
28 . A combined preparation according to claim 24 , or a pharmaceutical composition according to claim 26 , for use as a medicament.
29 . A combined preparation according to claim 24 , or a pharmaceutical composition according to claim 26 , for use in the treatment of pain.
30 . A combined preparation according to any one of claims 24 , 28 , and 29 or a pharmaceutical composition according to any of claims 28 to 29 , or a use according to claim 27 , or method according to claim 25 , wherein the steroid is a glucocorticoid.
31 . A combined preparation, pharmaceutical composition, use, or method according to claim 30 , wherein the steroid is selected from any one of prednisone, prednisolone, methyl prednisolone, triamcinolone, dexamethasone, hydrocortisone, deflazacort, betamethasone and budenoside.
32 . A combined preparation, pharmaceutical composition, use, or method according to any preceding claim, wherein the pharmaceutically acceptable salt is the mesylate salt.
33 . A combined preparation, pharmaceutical composition, use, or method according to any preceding claim, wherein the pharmaceutically acceptable salt is the sulphate salt, or a hydrate thereof.
34 . A method of treatment according to any preceding claim, wherein the treatment is treatment in a human subject.